Sie befinden sich hier

Inhalt

Mannheim Center for Translational Neuroscience

The Mannheim Center for Translational Neuroscience (MCTN) at Heidelberg University provides a platform for basic research-oriented, translational and clinical neuroscientists from the Medical Faculty Mannheim to work closely with the Central Institute for Mental Health, the life science research institutions of the University Heidelberg and with the non-university research institutions in the Rhine-Neckar metropolitan area.

Upcoming Talks and Events 

News

Making a personalized T cell therapy for cancer patients currently takes at least six months. Scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time. read more …

Researchers from the BioMed X Institute and the University Medical Centre Mannheim have published the results of their collaboration on a novel neoepitope vaccine against diffuse midline glioma in the journal Science Advances. read more …

Simon Wiegert receives ERC funding to develop a hyperspectral fiber photometry system that can be used flexibly for a wide range of optical measurements of brain function. read more …

At our Imaging in Neuroscience Symposium on December 7th at the University Hospital Mannheim, scientists presented their latest research and discussed new developments in the field of live imaging and the study of brain physiology and pathophysiology at different spatial and temporal scales. We look back on a very interesting and inspiring day with insightful presentations, interesting questions and important discussions with more than 90 attendees on site. read more ...

Neurologist and MCTN director Michael Platten and psychiatrist and CEO Andreas Meyer-Lindenberg from the Central Institute of Mental Health are listed among the world's most cited scientists in the category “cross field”.  read more …

Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time. The vaccine mimicked a mutational change in a histone protein typical of this type of cancer. The vaccine proved to be safe and induced the desired immune responses directed against the brain tumor. read more …

Two Collaborative Research Centers “Understanding and targeting resistance in glioblastoma” (CRC 1389), and “From nociception to chronic pain: structure-function properties of neural pathways and their reorganization” (CRC 1158) and the CRC/Transregio “Losing and Regaining Control over Drug Intake – From Trajectories to Mechanisms to Interventions” (CRC/TRR 265) in which MCTN members from the Medical Faculty of Mannheim  and  the Central Institute of Mental Health are involved have successfully qualified for a further funding period. read more …


Kontextspalte

ALUMNI

Prof. Dr. Rolf-Detlef Treede
(former MCTN Co-Director)

Prof. Dr. Martin Bohus